ISRCTN15279830进行中（未招募）2 期
A Phase II, randomised, single-blind, platform trial to assess safety, reactogenicity and immunogenicity of COVID-19 vaccines in pregnant women in the United Kingdom
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 319
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Healthy women =18 years of age who are between 13 0/7 and 34 0/7 weeks’ gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for obstetric complications
- •2. Able and willing (in the investigator’s opinion) to comply with all study requirements
- •3. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures
- •4. Willing and able to give informed consent prior to study enrolment
- •5. No contraindication to the specific vaccine to be administered in the study, according to the Green Book
排除标准
- •1. Previous microbiological (based on a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19
- •2. Administration of immunoglobulins and/or any blood products within the 3 months preceding the planned administration of the study vaccine candidate (with the exception of anti-D immunoglobulin)
- •3. Previous vaccination with any COVID-19 vaccine (main cohort); prior receipt of one dose of a COVID-19 vaccine is permitted (sub-study)
- •4. Any confirmed or suspected immunosuppressive or immunodeficient state; chronic administration (defined as more than 14 continuous days) of immunosuppressant medication within the past 3 months, except topical steroids or short-term oral steroids (course lasting =14 days)
- •5. Any contraindication to the specific vaccine to be administered in the study, according to the Green Book or to the Summary of Product Characteristics for a specific vaccine
- •6. Current major illness of the mother or conditions of the fetus that, in the investigator’s judgment, will substantially increase the risk associated with the participant’s participation in, and completion of, the study or could preclude the evaluation of the participant’s response, including but not limited to the following:
- •6.1. Uncontrolled gestational hypertension
- •6.2. Preeclampsia-eclampsia
- •6.3. Placental abnormality
- •6.4. Polyhydramnios or oligohydramnios
- •6.5. Significant bleeding or blood clotting disorder
- •6.6. Uncontrolled gestational diabetes
- •6.7. Any signs of premature labor with the current pregnancy or having ongoing intervention (medical/surgical) in the current pregnancy to prevent preterm birth
- •6.8. Prior stillbirth or neonatal death, preterm delivery (=34 weeks), or previous infant with a known genetic disorder or major congenital anomaly
研究者
相似试验
已完成
2 期
A phase II double-blind, randomised controlled trial of VEGF inhibitor axitinib monotherapy with early dynamic contrast-enhanced ultrasound monitoring in chemo-refractory third-line metastatic colorectal cancerCancerISRCTN70833965Imperial College of Science, Technology and Medicine (UK)51
进行中（未招募）
1 期
A study to test BI 767551 in people with mild to moderate symptoms of COVID-19.COVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-005588-29-BESCS Boehringer Ingelheim Comm. V200
进行中（未招募）
1 期
A study to test BI 767551 in people with mild to moderate symptoms of COVID-19.EUCTR2020-005588-29-NLBoehringer Ingelheim200
进行中（未招募）
1 期
A study to test BI 767551 in people with mild to moderate symptoms of COVID-19.COVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-005588-29-DEBoehringer Ingelheim Pharma GmbH & Co. KG200
进行中（未招募）
1 期
A study to test BI 767551 in people with mild to moderate symptoms of COVID-19.COVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-005588-29-ESBoehringer Ingelheim España, S.A.7